Table 3.

Risk factors for death-censored graft failure in recipients with polycystic kidney disease

Variable	Hazard Ratio (95% CI)		P Value
Age (per decade)	0.76 (0.6 to 0.96)		0.02a
Female sex	1.22 (0.82 to 1.81)		0.33
Non-White race	1.14 (0.51 to 2.55)		0.76
BMI (per 1 kg/m2 higher BMI)	1.04 (1.01 to 1.08)		0.03a
Dialysis before transplantation	1.26 (0.77 to 2.06)		0.35
Dialysis duration	1.00 (0.99 to 1.01)		0.42
Coronary artery disease	1.68 (1.03 to 2.76)		0.04a
Congestive heart failure	1.3 (0.61 to 2.74)		0.50
Polycystic liver disease	1.12 (0.72 to 1.74)		0.61
Deceased donor	1.62 (1.01 to 2.58)		0.05a
Donor age	1.36 (1.16 to 1.58)		<0.001a
Prior kidney transplantation	1.15 (0.58 to 2.26)		0.69
Induction treatment
Basiliximab	Reference
Thymoglobulinb	0.81 (0.46 to 1.43)		0.47
Alemtuzumab	1.12 (0.66 to 1.92)		0.65
Other	1.32 (0.60 to 2.90)		0.50
None	0.67 (0.22 to 2.03)		0.48
Calcineurin-inhibitor maintenance
Tacrolimus	Reference
Cyclosporine	0.69 (0.42 to 1.11)		0.12
None	1.80 (0.99 to 3.27)		0.06a
Mycophenolate maintenance	1.05 (0.49 to 2.28)		0.89
HLA mismatch
0–2	Reference
3–4	1.32 (0.77 to 2.27)		0.31
5–6	2.1 (1.20 to 3.64)		0.009a
Nephrectomy at transplantation	1.00 (0.64 to 1.54)		0.99a

BMI, body mass index.

^aP<0.05.

^bRabbit anti-thymocyte globulin.